The US Food and Drug Administration has approved the use of iTFlow in blood flow analysis. The FDA approval is significant as it recognizes the safety and effectiveness of iTFlow in analyzing blood flow through 4D Flow MRI data, with the potential to enhance diagnostic accuracy for patients with cardiovascular diseases and heart conditions.
The FDA approval of iTFlow will enable healthcare professionals to make more precise and effective decisions in patient care.
iTFlow is an software solution developed by Cardio Flow Design Inc. that supports blood flow analysis and evaluation in the fields of cardiovascular surgery and radiology. Based on MRI data, users can perform their own analysis and visualization of blood flow. It enables the visualization of fluid dynamics in the heart and blood vessels in both 2D and 3D, even without the use of contrast agents. Furthermore, various quantitative evaluations can be made, including flow rate, velocity, pathline, streamline, and other parameters. Combining advanced algorithms and image analysis techniques assists physicians and healthcare professionals in diagnosis and treatment planning.
Cardio Flow Design Inc. has been committed to strict quality management processes and efforts to comply with FDA standards in the development of iTFlow.
